China Biotech Services Holdings Limited

SEHK:8037 Stock Report

Market Cap: HK$264.9m

China Biotech Services Holdings Balance Sheet Health

Financial Health criteria checks 5/6

China Biotech Services Holdings has a total shareholder equity of HK$490.7M and total debt of HK$84.8M, which brings its debt-to-equity ratio to 17.3%. Its total assets and total liabilities are HK$662.4M and HK$171.6M respectively.

Key information

17.3%

Debt to equity ratio

HK$84.84m

Debt

Interest coverage ration/a
CashHK$72.09m
EquityHK$490.73m
Total liabilitiesHK$171.64m
Total assetsHK$662.36m

Recent financial health updates

Recent updates

China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

Mar 07
China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

Jan 18
Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Jan 06
We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

Dec 09
Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

Aug 24
These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

Nov 05
A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

Oct 13
Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

Jun 28
What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

Mar 16
China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Dec 01
China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

Jul 26
Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Apr 05
China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

Mar 23
Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

Feb 23
Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

Jan 28
Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?

Jan 11
What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?

The Trend Of High Returns At China Biotech Services Holdings (HKG:8037) Has Us Very Interested

Dec 08
The Trend Of High Returns At China Biotech Services Holdings (HKG:8037) Has Us Very Interested

Financial Position Analysis

Short Term Liabilities: 8037's short term assets (HK$261.2M) exceed its short term liabilities (HK$159.5M).

Long Term Liabilities: 8037's short term assets (HK$261.2M) exceed its long term liabilities (HK$12.2M).


Debt to Equity History and Analysis

Debt Level: 8037's net debt to equity ratio (2.6%) is considered satisfactory.

Reducing Debt: 8037's debt to equity ratio has increased from 1.5% to 17.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 8037 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 8037 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 45.8% per year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.